Roth/MKM recently commenced coverage on vTv Therapeutics (NASDAQ:VTVT), assigning a Buy rating accompanied by a price target set at $58. This projected valuation implies a substantial growth opportunity compared to the recent share price near $33.54, with analyst price expectations spanning from $35 to $67.
The research firm is particularly optimistic about vTv’s oral medication cadisegliatin, which is under development as a complementary treatment for type 1 diabetes (T1D). With approximately 80% of adults affected by T1D failing to meet the American Diabetes Association’s recommended A1C level below 7%, the company’s therapy addresses a significant gap in diabetes management.
Despite vTv Therapeutics not having reported profitability over the past twelve months, consensus analyst data indicate anticipated revenue growth within the current year, signaling potential market expansion. Roth/MKM emphasizes confidence in cadisegliatin’s approval prospects and widespread adoption, contingent on Phase 3 clinical trial outcomes replicating earlier favorable results. Importantly, vTv holds substantial market rights protected by patents extending through 2041, underpinning long-term commercial exclusivity.
Financial forecasts from the firm suggest peak unadjusted sales of roughly $1.5 billion by 2035 for cadisegliatin. A crucial upcoming event is the release of data from the Phase 3 CATT1 study, expected by year-end 2026, which represents a material catalyst for the company’s progress.
In terms of financial resources, Roth/MKM points out that vTv’s cash balance of $98 million as of the third quarter of 2025 should be adequate to sustain operations pending the outcome of the CATT1 trial, providing a runway without immediate financing concerns.
Complementing this outlook, vTv Therapeutics announced submission of a Phase 2 clinical study protocol to the Abu Dhabi Department of Health. This study aims to evaluate cadisegliatin’s efficacy as an adjunct treatment for insulin-dependent type 2 diabetes patients, expanding the therapeutic scope. The trial will be conducted in partnership with M42’s Insights Research Organization and Solutions and plans to enroll approximately 300 patients distributed across the United Arab Emirates, Jordan, and Tunisia.
Additional analyst activity includes H.C. Wainwright raising its price target for vTv Therapeutics from $36 to $47 while maintaining a Buy rating, prompted by the same Phase 2 trial protocol submission. Furthermore, TD Cowen has initiated coverage with a Buy rating and a higher price target of $67, highlighting the potential of cadisegliatin, a glucokinase activator, as a promising oral treatment currently progressing through Phase 3 trials for Type 1 diabetes mellitus.
These developments illustrate sustained interest in vTv Therapeutics’ clinical pipeline and ongoing positive evaluations from market analysts, reflecting a dynamic environment around the company’s therapeutic innovations.